New cancer drug trial seeks to shrink advanced tumors
NCT ID NCT02908906
Summary
This is an early-stage study testing a new immunotherapy drug called JNJ-63723283 in people with advanced cancers that have not responded to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors in cancers like lung cancer, melanoma, and bladder cancer. The study involves 413 participants and is no longer recruiting new volunteers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
St Louis, Missouri, United States
-
Study site
Pittsburgh, Pennsylvania, United States
-
Study site
Chisinau, Moldova
-
Study site
Bialystok, Poland
-
Study site
Warsaw, Poland
-
Study site
Moscow, Russia
-
Study site
Pyatigorsk, Russia
-
Study site
Saint Petersburg, Russia
-
Study site
Badalona, Spain
-
Study site
Barcelona, Spain
-
Study site
Madrid, Spain
-
Study site
Málaga, Spain
-
Study site
Pamplona, Spain
-
Study site
Seville, Spain
-
Study site
Valencia, Spain
-
Study site
Gothenburg, Sweden
-
Study site
Glasgow, United Kingdom
-
Study site
London, United Kingdom
-
Study site
Manchester, United Kingdom
-
Study site
Newcastle upon Tyne, United Kingdom
Conditions
Explore the condition pages connected to this study.